X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
These data are the first to show therapeutic efficacy of BNZ-1, a multi-cytokine inhibitor selectively targeting three interleukins, IL-2, IL-9, and IL-15. In the study, BNZ-1 treatment was well tolerated with no dose-limiting toxicities or drug-related serious side effects.
Lead Product(s): BNZ-1
Therapeutic Area: Oncology Product Name: BNZ132-1-40
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
This study followed a phase 1/2, multi-center, open-label, dose-escalation clinical study of BNZ-1 and was designed to assess its safety and activity as a single systemic agent in rCTCL patients that have failed standard of care and other available treatment options.
Lead Product(s): BNZ-1
Therapeutic Area: Oncology Product Name: BNZ132-1-40
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
The deal would expand Almirall's R&D pipeline with an additional three candidates on top of lead drug BNZ-1.
Lead Product(s): BNZ-1
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Almirall
Deal Size: $62.0 million Upfront Cash: $15.0 million
Deal Type: Collaboration January 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
